Abstract
Dicationic ruthenium(II)–p‐cymene complexes containing curcumin ligands (curcH = curcumin, bdcurcH = bisdemethoxycurcumin) and ionic N‐methyl‐1,3,5‐triaza‐7‐phosphaadamantane [PTA‐Me]X (X = BF4 or I) have been synthesized and fully characterized for the first time. The solid‐state structure of [Ru(p‐cym)(curc)(PTA‐Me)][SO3CF3][BF4] has also been determined by single‐crystal X‐ray diffraction. Modest antiproliferative activities of the complexes were observed against cisplatin‐sensitive and cisplatin‐resistant human ovarian carcinoma cells (A2780 and A2780cisR, respectively) and nontumorigenic human embryonic kidney (HEK293) cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
